Inclusion Criteria:  Informed Consent as documented by signature (Appendix Informed Consent Form), age 40-80, ≥5 years of education, previous evidence of brain amyloidosis (assessed by PET, CSF, or blood-based biomarkers).  Exclusion Criteria:  history of epilepsy; clinically relevant visual or auditory diseases/deficits; clinical diagnosis of dementia; contraindication to amyloid-PET; inability to undergo the procedures of the study, e.g. severe behavioral disturbances;  severe diseases:  Malignant neoplasm within 5 years, Life threatening diseases, Severe systemic diseases (e.g. kidney insufficiency, cardiac insufficiency, decompensated diabetes, decompensated metabolic diseases, decompensated hypothyroidism, uncontrolled autoimmune diseases); the participation to a clinical trial involving potential Alzheimer's disease modifying therapies; documented pregnancy or intention to become pregnant during the course of the study or breast feeding.